MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 8 Hold Rating(s), 9 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Buy (Score: 2.61)
Consensus Price Target: $28.82 (11.99% downside)

Current Analysts' Coverage Summary for Sarepta Therapeutics (NASDAQ:SRPT)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015OppenheimerReiterated RatingBuy$45.00 -> $28.18View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015Robert W. BairdReiterated RatingBuy$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015SunTrustReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015RBC CapitalSet Price TargetHold$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Deutsche BankReiterated RatingHold$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015William BlairReiterated RatingOutperform$34.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/23/2015Piper JaffrayReiterated RatingNeutral$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2015WBB SecuritiesReiterated RatingStrong-Buy$25.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/21/2015Bank of AmericaDowngradeBuy -> Neutral$20.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Cowen and CompanyReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015WedbushBoost Price TargetNeutral$16.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Needham & Company LLCReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Credit SuisseReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/22/2014Citigroup Inc.UpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2014SidotiInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013Leerink SwannLower Price TargetMarket Perform$44.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013FBR & Co.Lower Price TargetMarket Perform$48.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2013Janney Montgomery ScottDowngradeNeutral -> SellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/5/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha